

Interim Report

JANUARY 1 – JUNE 30, 2022



Sortland Lofoten, Norway

ChromoGenics increases order intake and focus on reducing costs

Q2 2022

- ChromoGenics continues its positive development with a strong focus on customers and quality, higher order intake, and measures to lower costs and improve efficiency.
- During Q2 2022, ChromoGenics delivered the last glass for the Gullhaugs Torg project in Oslo. The control system will be installed as the building is completed. Calibration of control systems and the final inspection of the project remain and are expected to be completed in Q3 2022.
- During the quarter, ChromoGenics received a number of new orders, primarily for ConverLight® Dynamic but also for ConverLight® Static, to, for example,
- Kvarteret Kransen 2, an office property in Uppsala, for ConverLight® Static. The order, which is valued of SEK 1.4 million, will be delivered in 2022. The office property will be upgraded with modern glass in existing windows, which improves the indoor climate and reduces energy use.
- First order to Germany. The delivery includes ConverLight® Dynamic for an office property and is valued of SEK 0.3 million. The transaction is occurring in close cooperation with partners from the German glass industry. ChromoGenics is thus taking the next step in its strategy to focus on delivery of dynamic film and related control systems. The company's partners are responsible for glass deliveries, IGU manufacturing, fitting in frames and installation in the property.
- Another order for ConverLight® Dynamic to Norway. The customer, the municipality building in Nannestad, north of Oslo, is pursuing a renovation and extension project to improve the standard of the office environment. The order is valued of SEK 1.1 million.
- The company received a new order for ConverLight® Dynamic glass and control system for a nursing home in Jönköping, Willhelmsrogården, for a total value of around SEK 0.7 million for delivery in the fall.
- Yet another order for ConverLight® Dynamic glass and control system was received for a municipal assisted living facility, Katedern 12 in Gamleby valued of SEK 1.1 million, with delivery around the start of the new year. The project will be delivered in cooperation with LEIAB, a Swedish manufacturer of quality windows for the Scandinavian market. For the property owner Västervik Bostad, the measure entails better energy efficiency, lower operating expenses and improved comfort for the tenant. For the residents, it is also particularly good that the difference between shadows and light is toned down.
- Since ChromoGenics is completing its deliveries for the project at Gullhaugs Torg in Oslo, the company is adapting its costs by releasing hired staff. At the same time, the company has made advancements in its productivity and efficiency in the past few quarters, which has further reduced the need for hired staff. The change entered into force after the vacation period with savings of around SEK 2.5 million (SEK 6.0 million in full-year effect).
- After having resolved the CFO-role the past few years on a consultancy basis, ChromoGenics has now completed its recruitment of a permanent CFO. Erik Elfström will take on the role of CFO & Head of Investor Relations on September 1, 2022.

- After having declined re-election, Claes-Göran Granqvist will leave the Board of Directors of ChromoGenics AB after nineteen years, the company that he himself helped found. The Annual General Meeting in May appointed Fredrik Andersson, Market Area Director for Systemair, as a new Board member. Systemair contributes to improving the indoor climate through energy-efficient and sustainable products that reduce carbon emissions.
- Some customers who received glass deliveries before ChromoGenics started its in-house production would like their glass to be replaced. A number of projects were manufactured during the quarter. Provisions were made for the costs for these redeliveries, but liquidity was impacted negatively during the quarter.
- In Q2 2022, ChromoGenics' net sales amounted to SEK 2.8 (1.7) million, an increase of SEK 1.1 million compared to the corresponding quarter in 2021.
- The operating loss for Q2 2022 amounted to SEK -14.8 (-28.8) million. The loss in the previous year was impacted negatively by a provision for redeliveries of SEK 17.2 million. Excluding redeliveries, earnings were negatively impacted by around SEK 3.2 million, attributable to increased costs for raw materials and transports.
- For the period April–June 2022, profit after tax amounted to SEK -15.6 (-29.8) million, which corresponds to earnings per share of SEK -0.91 (-4.21), basic, including warrants (TO4) from the unit issue in March 2022.
- Order intake for Q2 2022 amounted to SEK 7.6 (0.5) million. The order volume for Q2 2022 amounts to around SEK 7.8 (28.5) million.
- Cash and cash equivalents amounted to SEK 22.9 (48.5) million on June 30, 2022.

EARNINGS PERFORMANCE IN SUMMARY

<i>SEK million</i>	2022	2021	2022	2021	2021
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Net sales	2,8	1,7	11,3	3,3	24,7
EBITDA	-13,9	-28,3	-30,0	-37,6	-57,4
Net income	-15,6	-29,8	-33,2	-40,5	-63,5
EPS before dilution, SEK	-0,91	-4,21	-1,95	-5,72	-8,98
Cash and bank end of the period	22,9	48,5	22,9	48,5	18,9

EVENTS AFTER THE END OF THE PERIOD

- In August, ChromoGenics received a final order from Aluflam for dynamic glass for the school Prins Henrik Skole in Copenhagen. In total, the order is for around 1,000 m² and has a value of around SEK 5 million. Deliveries will commence in Q3 2022, and the majority of the order is expected to be delivered in 2022. The transaction is occurring in close cooperation with Aluflam, a Danish quality supplier of glass and facade solutions. ChromoGenics is thus entering the Danish market and following its strategy to focus on delivery of dynamic film and related control systems. Aluflam is responsible for glass deliveries, IGU manufacturing and installation in the property.
- Breakthrough in own process development creates the opportunity to reduce the direct material costs for ConverLight® Dynamic by approx. 40% by replacing purchased material with own, internal production.

ChromoGenics is using plastic film coated with indium-tin-oxide (ITO) as an input material in its manufacturing process.

- On July 26, 2022, ChromoGenics announced that it had received new orders for ConverLight® Static of around SEK 1.1 million for Humlegården's property Stora Blå in Solna and Vasakronan in Uppsala with delivery in the fall. The projects are being delivered in cooperation with Bollan AB.
- On August 9, the company announced changes to its management team. Victor Hägglund was named COO and will take an overarching responsibility for purchasing, production and supply chain. Fredrik Fränding, currently the CEO, will therefore take over as Acting Head of Sales. Linus Wetterlind is leaving the company at the end of September.

Comments from the CEO

ChromoGenics is a proptech company that contributes to more sunlight and well-being indoors, higher energy efficiency, and a decreased impact of the real estate industry on the climate.

We are seeing positive effects from our work with measures to create greater value. During the quarter, we have seen improved order intake and taken important steps to lower our costs. The period was impacted by increased contact with customers to strengthen order intake, efforts to reduce production costs, and the manufacturing of glass for faulty delivered projects.

Increased focus on growth after achieved milestones

Over the past year, the company has achieved a number of milestones. In June 2021, the company announced that we could deliver a tested and quality assured product from our own factories. Focus then shifted to redirect all available funds to rapidly scaling up production and delivering more than SEK 30 million in booked orders. The company also achieved this milestone in a very challenging global market that was impacted by COVID-19, global logistics and delivery disruptions, and sharply rising material costs.

We have delivered the glass for our large project in Oslo, and as the building takes shape the control system will be installed. However, the project has been impacted by increased costs and delays. We expect to be able to transfer the project in the third quarter. We also successfully delivered a number of smaller projects during the first six months of 2022.

The company is now fully focused on growing our business and delivering quality products at a good gross margin. The efforts in the second quarter to improve the production outcome, raise efficiency and lower raw material costs are

expected to improve the gross margin in future quarters.

Cost focus continues

ChromoGenics is using plastic film coated with indium-tin-oxide (ITO) as an input material in its manufacturing process. Since the company restarted production last year, deliveries of ITO-coated plastic film have been burdened by recurring delivery and quality problems as well as significant costs.

Therefore, the company worked for some time to establish and assure its own production of ITO in our sputtering factory. This work was concluded in the second quarter, and after the end of the quarter, the first production batches were manufactured with good results. We estimate that, by producing ITO in-house, we will lower our direct material costs for ConverLight® Dynamic by around 40%. In-house production will also reduce both transport costs and production disruptions. Eliminating air transport from the USA will also further improve ChromoGenics' already excellent environmental classification.

Given that the project at Gullhaugs Torg in Oslo, Norway, is closing, we have also adapted our costs by releasing hired staff, which means a reduction in staff of 28%. We also made advancements in efficiency in the past few quarters, which has further reduced the need for hired staff.

To accelerate the work with cost reductions and efficiency improvements, the company made a number of changes to its organization. Victor Hägglund has been named COO and will take an overarching responsibility for purchasing, production and the supply chain with the goal of driving and quantifying cost reductions and efficiency improvements. Erik Elfström has been recruited to the role of CFO and will start in September.

During the quarter, production focused on manufacturing replacement glass for a number of faulty deliveries from 2019 before ChromoGenics started its in-house production. This manufacturing has had a limited impact on earnings during the quarter but had a negative impact on our cash and cash flow.

Profit for the period and cash flow were also negatively impacted by the significant cost increases for materials and transports. For example, prices on insulating glazing units increased by around 50% the past year. We are seeing good possibilities for transferring these costs to customers for new orders, but the possibilities for transferring cost increases have been limited for faulty delivered projects and delivery agreements that have already been entered into.

Improved order intake

During the quarter, we won a number of new orders for both ConverLight® Dynamic and Static, which resulted in improved order intake compared to the past few quarters. Despite general market uncertainty, particularly in the real estate sector, we are still seeing strong interest in our products. Our focus continues to be on increasing the conversion rate of interest and business opportunities to booked orders. We are also building our sales network in collaboration with competent partners.

An important order for us is the order of around SEK 5 million from Aluflam for the school Prins Henrik Skole in Copenhagen. This order enables us to take yet another step in our strategic direction: focusing our operations on the development and manufacture of dynamic film and related control systems. Since our partner Aluflam is responsible for the glass deliveries, this lowers ChromoGenics' net sales, but we are lowering our costs, streamlining the business and raising our gross margin.

During the quarter, we also delivered a smaller project to Germany. This is our first delivery to this large and growing market for dynamic glass. Even in this case, our partners in Germany are responsible for the glass deliveries and the installation. An important step for our future growth and scalability.

We are seeing good growth in business opportunities in not only Sweden and Norway, but also Denmark, Finland, Germany and Switzerland. Renovations and energy efficiency improvements of office properties from the '70s and '80s, but also even the '90s, present attractive opportunities for our products. We are also seeing considerable interest from schools and special residences, where the indoor environment is of crucial importance for study results and well-being.

Despite an uncertain economy, we are continuing to see strong interest in taking measures to reset the real estate industry, particularly through energy efficiency improvements. Upgrading windows and glass facades with modern technology is a cost-efficient way to achieve energy efficiency, a reduced impact on the climate and, not least, an improved indoor environment.

Fredrik Fränding, CEO



Q2 2022


NET SALES

In Q2 2022, ChromoGenics' net sales amounted to SEK 2.8 (1.7) million, an increase of SEK 1.1 million compared to the corresponding quarter in 2021.


During Q2 2022, ChromoGenics delivered the last glass for the Gullhaugs Torg project in Oslo. The final inspection of the project remains and is expected to be completed in Q3 2022.

In addition, the company produced glass for a number of smaller projects and for some redeliveries that the company committed to rectify. These redeliveries do not impact sales.

Total net sales of dynamic glass in the second quarter amounted to around SEK 2.1 (0.2) million. Net sales for static products amounted to approximately SEK 0.7 (1.5) million.



During the quarter, the company won a number of new orders for both ConverLight® Dynamic and Static, which resulted in improved order intake compared to the past few quarters. The company's focus continues to be on increasing the conversion rate of interest and business opportunities to booked orders.



Work performed for the company's own use and capitalized amounted to SEK 0.7 (1.1) million and refers to the capitalization of R&D expenditure for new products, such as wireless control of the dynamic products.

Other operating income amounted to around SEK 0.3 (0.3) million in Q2 2022 and refers primarily to exchange rate fluctuations to the euro.

COST DEVELOPMENT

Costs in focus – has impacted ChromoGenics during the second quarter in terms of both cost of goods and operating costs. Delivery and quality problems related to input goods from some suppliers in the first quarter have improved, but after-effects remained during the quarter.

We are clearly seeing an increase in costs in the wake of external changes:

- Tempered glass +100%
- Insulating glass units (IGU) +50%
- Transports +10–15%
- Electricity +40% (around 3% of operating expenses)

ChromoGenics sees good possibilities for transferring these costs to customers for new orders, but the possibilities for transferring cost increases have been limited for faulty delivered

projects and delivery agreements that have already been entered into. Costs for redeliveries are met by a provision made the previous year.

Despite tough times, ChromoGenics has successfully raised gross profit and reversed the negative trend from previous quarters. A gross profit of 11.2 percent is a step in the right direction compared to the gross profit in the first quarter of SEK -0.8 percent.

The possibility of raising gross profit is deemed to be good. Efforts to improve the production outcome, raise efficiency and lower raw material costs are accelerating, and tests to produce ITO in-house have had positive results. A lot of time has been spent producing and quality assuring in-house ITO production in our sputtering factory. The first production batches were manufactured at the start of the third quarter. The direct material cost for ConverLight® Dynamic is thus estimated to be reduced by around 40%.

In order to offset a lower order intake from previous quarters and that ChromoGenics has completed delivery of large parts of the Gullhaugs Torg project in Oslo, the company is adapting its costs by releasing hired staff, which corresponds to a drop in personnel of -28 percent in total. The change goes into effect as of June 30 with expected savings of around SEK 2.5 million (SEK 6.0 million for the full-year effect).

Parts of the provision for redeliveries were used during the quarter: SEK -1.3 million. In the third quarter, accrued costs for redeliveries were recorded against the provision. The provision amounted to SEK 20.2 (21.5) million at the end of the period.

Other external costs amounted to SEK -7.2 (-23.3) million. Taking into consideration the provisions for redeliveries that was made last year of SEK 17.2 million, the period's increase is SEK 1.1 million. The increase in cost is primarily attributable to extra hired staff of SEK 0.8 million and costs of premises of SEK 0.3 million for the sputtering factory.

Personnel costs in Q2 2022 amounted to SEK -7.0 million compared to SEK -5.6 million last year. The higher personnel costs in Q2 2022 are attributable primarily to new employees in sales, glass lamination and sputter production.

Depreciation on fixed assets amounted to SEK -0.9 (-0.5) million. The company applies a production-dependent depreciation method to the sputtering machines. The depreciation is charged at the rate of the produced units.

Other operating costs of SEK -0.1 (-0.1) million refer to the negative exchange rate effect on the quarter's operating costs due to the depreciation of the Swedish krona.

ChromoGenics' operating loss for the second quarter of the year amounted to SEK -14.8 (-28.8) million, which is an improvement of SEK 14.0 million compared to the corresponding quarter in 2021. Taking in consideration the redelivery provision of SEK 17.2 million, the operating loss fell by SEK 3.2 million.

Net financial items for the period April–June 2022 amounted to SEK -0.8 (-1.0) million and are primarily related to interest expenses for the conditional loans from the Swedish Energy Agency.

Tax – Change in deferred tax is related to financial leasing SEK 3 (0) thousand.

Profit/loss for Q2 2022 amounted thus to SEK -15.6 (-29.8) million, an improvement of SEK 14.2 million compared to the corresponding period in 2021. Taking into consideration the redelivery provision, it was a decline of SEK 3.0 million

CASH FLOW

Cash flow from operating activities before changes in working capital amounted to SEK -31.6 (-39.1) million, an improvement of SEK 7.5 million related to the improved operating profit during the period Jan–June 2022.

Cash flow from operating activities including the change in working capital amounted to SEK -36.1 (-35.8) million for the period Jan–June 2022. The negative change in cash flow from operating activities in 2022 of SEK 0.4 million is related to the increase in inventories.

Net cash flow from investing activities amounted to SEK -4.2 (-9.0) million for the period. The investments in intangible assets amounted to SEK -3.1 (-3.1) million and are related to ongoing process development for a new production line for sputtered film and product development of wireless control. Acquisitions of property, plant and equipment amounted to SEK -1.1 (-5.8) million and refer to the renovation in a third party's property of electricity for the production facility on Söderforsgatan and expenses for the installation of Sputter II.

Net cash flow from financing activities amounted to SEK 44.4 (-0.2) million during the period Jan–June 2022. In February–March 2022, a preferential rights issue was conducted that generated a capital contribution net after issue expenses of SEK 40.9 million.

Cash flow for the period amounted to SEK 4.0 million compared to SEK -44.9 million for the corresponding period in 2021.

FINANCIAL POSITION

The balance sheet total at the end of the period on June 30, 2022, amounted to SEK 171.9 (186.9) million, a decrease of -15.0 million in twelve months. The company's fixed assets increased by SEK 8.2 million compared to one year ago and are primarily attributable to the past year's investments of SEK 7.0 million in property, plant and equipment. Most of this refers to the completed installation of Sputter I. In current assets, inventories increased by SEK 9.8 million over the past twelve months at the same time as accounts receivable and other current receivables decreased by SEK -7.4 million.

Cash and cash equivalents amounted to SEK 22.9 million on June 30, 2022, compared to SEK 48.5 million on June 30, 2021. This entails a decrease in cash and cash equivalents by SEK 25.6 million for the past twelve months.

Equity at the end of the period amounted to SEK 69.0 million, of which restricted equity amounted to SEK 12.7 million and unrestricted equity to SEK 56.3 million. For the same period in 2021, equity amounted to SEK 80.3 million.

Adjusted equity considering two conditional loans from the Swedish Energy Agency amounted to SEK 116.6 million compared to the opening balance for the year of SEK 105.3 million and SEK 127.9 million one year ago.

In October 2020, ChromoGenics was granted a deferment until October 1, 2022, for its repayment obligation on the conditional loans from the Swedish Energy Agency, which means current liabilities of around SEK 11.2 million were reclassified as non-current liabilities. During Q4 2021, SEK 15.1 million of the long-term interest-bearing liabilities once again became current interest-bearing liabilities. Long-term liabilities amounted to SEK 50.6 (65.4) million as at June 30, 2022.

Current liabilities amounted at June 30, 2022, to SEK 52.3 (41.2) million, of which interest-bearing current liabilities amounted to SEK 18.1 (0.0) million. The equity/assets ratio as per June 30, 2022, amounted to 68.5 (68.4) percent.

INVESTMENTS

Investments in Q2 2022 amounted to SEK -3.1 (-4.6) million, of which SEK -2.3 (-1.4) million refers to intangible assets associated with the product development of wireless control of the dynamic glass and the new production line of sputtered film. The acquisition of property, plant and equipment amounted to SEK -0.8 (-3.1) million. The cost amount refers to the upgrade of electricity capacity for the sputtering factor and preparatory steps for the installation of Sputter II.

EMPLOYEES

The average number of employees (FTEs) in Q2 2022 amounted to 34 (24). The average number (FTEs) including hired staff and consultants amounted to 47 (36) during the second quarter, which is 11 more than in the same quarter in 2021, which shows the higher activity level in the business. The number of employees including hired staff and consultants amounted to 31 full-time positions after the communicated reductions as per June 30, 2022.

SHARE CAPITAL

The most recent change to the share capital was registered on May 9, 2022, and was due to a holder of warrants, TO3, redeeming them for shares, which increased the number of shares by 3,098 and the share capital by SEK 619.20, and a guarantor in the most recent preferential issue choosing to receive payment in the form of shares instead of cash. At the beginning of May, the company made a private placement of 80,000 shares for the guarantor, which increased the number of shares to 35,266,585 and share capital to SEK 7,053,316.40.

The warrants issued in conjunction with the preferential rights issue entitle the holder, during the period March 13 – 27, 2023, to subscribe to a new share in ChromoGenics for four (4) warrants. The exercise price corresponds to seventy (70) percent of the volume-weighted average price paid for ChromoGenics' share on Nasdaq First North Growth Market during the period February 21 – March 7, 2023, however at a minimum of SEK 2.50 and a maximum of SEK 4.50. This means that ChromoGenics, upon full exercise of the warrants, may also receive around SEK 20.5 million.

SHAREHOLDERS

Since March 23, 2017, ChromoGenics' shares and warrants have been traded on Nasdaq First North Stockholm with Erik Penser Bank AB as Certified Adviser as of December 2019.

The largest shareholders as per June 30, 2022, are presented in the following table:

Shareholders per 2022-06-30	Ordinary shares	Votes and capital
RGG ADM-Gruppen AB	2 893 623	8,20%
Färna Invest AB	2 404 136	6,82%
Avanza Pension	2 180 281	6,18%
UBP Clients Assets - Sweden	1 261 907	3,58%
Nordnet Pensionsförsäkring AB	821 907	2,33%
Formue Nord Markedsneutral A/S	780 535	2,21%
Bengt Josefsson Utveckling AB	700 000	1,98%
SEB Pank AS, NQI	698 661	1,98%
Corespring Invest AB	692 293	1,96%
Brandt, Barbro	576 000	1,63%
Övriga	22 257 242	63,11%
Totalt	35 266 585	100,00%

Source: Euroclear AB

According to Euroclear, there were 6,236 shareholders at the end of the period.

SIGNIFICANT RISKS AND UNCERTAINTY FACTORS

The company is exposed to a number of financial risks: liquidity risk, credit risk and currency risk. The Board of Directors and the company's management team manages these risks by on a regular basis identifying, evaluating and, where appropriate, offsetting and counteracting them.

Liquidity risk

Cash and cash equivalents amounted to SEK 22.9 million on June 30, 2022.

ChromoGenics' future capital needs are determined by a large number of factors, such as the planned rate of expansion, product and process development, investment needs, and the company's sales development and achieved gross margins.

The Board is reviewing on a continuous basis several conceivable scenarios, each of which has a different need for financing. Financing in turn can be raised from different sources and carried out in different ways depending on prevailing market conditions. The Board continues to see good possibilities for successfully securing long-term financing for the company. The goal is for customers and suppliers to view ChromoGenics as a stable company.

If the company's cash and cash equivalents do not cover the need for financing up until the point in time when the company achieves a

positive cash flow from its operating activities, and if the company does not successfully secure long-term financing, there is a risk that this will ultimately lead to the winding down of the company.

Currency risk

Normally, a significant portion of the company's sales is in SEK. The ongoing project Gullhaugs Torg 5 in Oslo is being invoiced in EUR. If there are sales in USD, EUR and/or NOK, and these currencies appreciate against SEK, this will have a positive effect. A significant percentage of the material and process costs currently occur in USD and EUR and are translated/reported into SEK on payment days. If USD and/or EUR appreciates against SEK, this will have a negative effect on the company's costs. The company is thus directly dependent on the exchange rates of these currencies.

Employees

ChromoGenics currently has an organization consisting of approximately 31 employees, including temporary staff and consultants, and is dependent on a number of key staff members. A weak financial position and weak profitability during the company's growth phase can limit the possibility of recruiting and keeping key staff members.

AUDITOR'S REVIEW

This year-end report has not been reviewed by the company's auditor.

CALENDAR

August 25, 2022	Interim Report January–June 2021
November 18, 2022	Interim Report January–September 2022
February 17, 2023	Year-End Report 2022
May 25, 2023	Interim Report January–March 2023

The Board of Directors and CEO hereby confirm that the interim report provides a fair and accurate view of the company's operations, position and performance and describes the significant risks and uncertainty factors facing the company.

Uppsala, August 24, 2022

ChromoGenics AB (publ) CIN 556630-1809

Anders Brännström
Board member

Johan Hedin
Chair of the Board of Directors

Mari Broman
Board member

Fredrik Andersson
Board member

Andreas Jaeger
Board member

Fredrik Fränding
CEO

For more information, please contact:

Fredrik Fränding, CEO: +46 72 249 24 62

Göran Atterling, CFO & Head of Communications: +46 70 380 95 00

This report, together with previously published interim reports, can be found in its entirety on the company's website.

<https://chromogenics.com/financial-reports/>

This information constitutes such information that ChromoGenics AB is obligated to disclose in accordance with the EU Market Abuse Regulation. The information was submitted by the above-mentioned contact persons for publication on August 25, 2022, at 08:30 CET.

ABOUT CHROMOGENICS

ChromoGenics is a proptech company producing smart dynamic glass that improves indoor environments and well-being and lowers buildings' energy consumption, operating expenses and impact on the climate. The company's product ConverLight® Dynamic is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic film. The result is a dynamic film that can be laminated between glass layers, which provides buildings with good solar protection and lowered environmental impact from production, transport and use. The dynamic film is easy to transport and can be applied by local partners in the glass industry, which means it is possible to avoid long-distance shipping of bulky glass. All of ChromoGenics' products strive to follow the key words *environment* and *health*. This means a focus

on environmentally friendly material, lower energy consumption, increased access to daylight and views and improved indoor comfort.

The company's production facilities in Uppsala have been financed in part by a conditional loan from the Swedish Energy Agency. ChromoGenics' share (CHRO) is listed on Nasdaq First North Growth Market, and Erik Penser Bank is the Certified Adviser: certifiedadviser@penser.se, +46 8 463 83 00.

info@chromogenics.com

Certified Adviser: Erik Penser Bank AB

Financial Statements:

Income Statement

Balance Sheet

Statement of Cash Flows

Statement of Changes in Equity

Notes

Income Statement per Individual Quarter

Statement of Cash Flows per Individual Quarter

Income Statement

KSEK	2022	2021	2022	2021	2021
	Apr-Jun	Apr-Jun	Jan-Jun	Jan-Jun	Jan-Dec
Net sales	2 802	1 682	11 317	3 298	24 690
Change in inventories of products in progress	-477	-1 209	-911	-1 523	922
Capitalized own work	696	1 149	1 340	2 469	4 536
Other operating income	255	276	809	345	1 295
Gross operating income	3 275	1 898	12 554	4 589	31 443
Raw materials and consumables used	-2 909	-1 305	-12 266	-2 900	-21 399
Other external costs	-7 203	-23 295	-15 634	-28 372	-44 470
Personnel costs	-7 022	-5 588	-14 006	-10 735	-21 941
Depreciation of intangible assets and tangible assets	-866	-456	-1 576	-937	-2 286
Other operating expenses	-70	-55	-657	-220	-1 002
Total operating expenses	-18 071	-30 699	-44 140	-43 164	-91 098
Operating income	-14 795	-28 801	-31 585	-38 575	-59 655
Interest income	24	33	29	66	101
Interest expenses	-805	-1 023	-1 617	-1 973	-3 979
Total result of financial items	-781	-990	-1 588	-1 907	-3 878
Operating income after financial items	-15 576	-29 791	-33 173	-40 482	-63 533
Tax	3	0	3	0	0
Net income	-15 573	-29 791	-33 170	-40 482	-63 533

Balance Sheet

KSEK	2022 30-jun	2022 31-mar	2021 31-Dec	2021 30-Sep	2021 30-Jun
ASSETS					
Non-current Assets					
Intangible assets	12 846	10 958	10 513	10 182	9 358
Property, plant and equipment	103 379	102 356	101 794	100 621	96 364
Financial assets	2 066	2 479	2 452	2 443	4 348
Total non-current assets	118 291	115 793	114 759	113 246	110 070
Current Assets					
Inventories and work in progress	17 398	13 831	11 011	13 322	7 617
Trade receivables	6 891	9 893	8 857	12 758	9 936
Other current receivables	6 393	7 426	6 966	12 145	10 770
Cash and cash equivalents	22 895	49 393	18 851	28 214	48 495
Total current assets	53 577	80 543	45 685	66 439	76 818
TOTAL ASSETS	171 868	196 336	160 444	179 685	186 888
EQUITY AND LIABILITIES					
Equity					
<i>Restricted equity</i>					
Share capital	7 037	7 037	3 408	3 408	3 395
Fund, development expenses	5 616	5 616	3 562	1 779	1 779
<i>Non-restricted equity</i>					
Share premium reserve	691 185	691 575	650 330	650 340	649 880
Accumulated profit/loss	-601 652	-601 652	-536 065	-534 282	-534 281
Operating income for the period	-33 170	-17 597	-63 533	-47 733	-40 482
Total equity	69 015	84 979	57 702	73 512	80 291
Liabilities					
Non-current liabilities					
Non-current interest-bearing liabilities ¹⁾	46 753	46 733	46 264	59 939	59 012
EU contribution	3 839	3 839	3 839	3 959	6 343
Total non-current liabilities	50 591	50 572	50 103	63 898	65 355
Current liabilities					
Current interest-bearing liabilities ¹⁾	18 067	16 485	15 434	0	0
Trade payables	7 523	13 032	7 772	11 145	6 728
Other current liabilities	26 671	31 268	29 433	31 130	34 514
Total current liabilities	52 261	60 785	52 639	42 275	41 242
TOTAL EQUITY AND LIABILITIES	171 868	196 336	160 444	179 685	186 888

¹⁾ Where of 62 598 KSEK Refers to soft loans from the Swedish Energy Agency.

Statement of Cash Flows

KSEK	2022 Apr-Jun	2021 Apr-Jun	2022 Jan-Jun	2021 Jan-Jun	2021 Jan-Dec
OPERATING ACTIVITIES					
Profit/loss before tax	-14 795	-28 801	-31 585	-38 575	-59 655
Financial income and expenses	-781	-990	-1 588	-1 907	-3 880
<i>Adjustments for non-cash items:</i>					
Contribution from EU	-	48	-	417	-
Capital gain sold fixed assets	0	0	0	0	0
Depreciation/amortization and impairment	866	456	1 576	937	2 286
Cash flow from operating activities before changes in working capital	-14 710	-29 287	-31 597	-39 128	-61 249
<i>Cash flow from changes in working capital</i>					
Increase(-)/decrease(+) inventories	-3 567	-563	-6 387	628	-2 766
Increase(-)/decrease(+) trade receivables	3 002	468	1 966	-7 711	-6 632
Increase(-)/decrease(+) current receivables	1 451	47	963	-3 252	2 867
Increase(+)/decrease(-) trade payables	-5 509	-635	-249	-1 421	-377
Increase(+)/decrease(-) current liabilities ¹⁾	-3 638	13 850	-844	15 114	9 405
Cash flow from changes in working capital	-8 261	13 167	-4 551	3 358	2 497
Cash flow from operating activities	-22 971	-16 120	-36 148	-35 770	-58 752
INVESTING ACTIVITIES					
Acquisition of intangible assets	-2 256	-1 414	-3 070	-3 131	-4 985
Acquisition of property, plant and equipment	-798	-3 149	-1 096	-5 838	-11 006
Cash flow from investing activities	-3 055	-4 563	-4 167	-8 969	-15 991
FINANCING ACTIVITIES					
New share issue	-389	-4	44 485	-156	306
Repayment of leasing debt	-83	-	-126	-	-102
Cash flow from financing activities	-472	-4	44 359	-156	204
CASH FLOW FOR THE PERIOD	-26 498	-20 687	4 044	-44 895	-74 539
CASH AND CASH EQUIVALENTS AT START OF THE PERIOD	49 393	69 182	18 851	93 390	93 390
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	22 895	48 495	22 895	48 495	18 851

Statement of changes in equity

KSEK	Share capital	Fund, development expenses	Share premium reserve	Accumulated profit/loss	Total equity
Equity 1 Jan 2021	3 395	1 779	650 037	-534 282	120 929
New share issues					0
New share issue fees			-156		-156
Operating income for the period				-40 482	-40 482
Equity 30 Jun 2021	3 395	1 779	649 881	-574 764	80 291

KSEK	Share capital	Fund, development expenses	Share premium reserve	Accumulated profit/loss	Total equity
Equity 1 Jan 2022	3 408	5 616	650 330	-601 652	57 701
New share issues	3 629		50 808		54 438
New share issue fees			-9 953		-9 953
Operating income for the period				-33 170	-33 170
Equity 30 Jun 2022	7 037	5 616	691 185	-634 823	69 015

Among the company's liabilities is a soft loan from the Swedish Energy Agency which, according to the loan agreement and the regulations set out in the Swedish Companies Act (25:14), may be eliminated upon preparation of a balance sheet for liquidation purposes. The utilized soft loan from the Swedish Energy Agency amounted to SEK 47.6 million. Equity taking into account the soft loan, i.e. adjusted equity, amounted to SEK 116.6 million (127.9) as per June 2022 and SEK 105.3 million as per December 31, 2021.

Noter

Not 1, Redovisningsprinciper

ChromoGenics upprättar sin redovisning baserat på Årsredovisningslagen och Bokföringsnämndens allmänna råd BFNAR 2012:1, Årsredovisning och koncernredovisning (K3). Bolaget tillämpar en produktionsberoende avskrivningsmetod avseende sputtermaskinerna. Avskrivningen sker i takt med med producerande enheter. För övriga anläggningstillgångar tillämpas linjär avskrivningsmetod. I övrigt är redovisnings- och värderingsprinciperna år oförändrade jämfört med föregående år.

Income Statement per isolated quarter

KSEK	2021 Iso. Q1	2021 Iso. Q2	2021 Iso. Q3	2021 Iso. Q4	2022 Iso. Q1	2022 Iso. Kv.2
Net sales	1 616	1 682	7 734	13 658	8 515	2 802
Change in inventories of products in progress	-314	-1 209	2 669	-224	-434	-477
Capitalized own work	1 320	1 149	1 281	786	644	696
Other operating income	69	276	127	823	554	255
Gross operating income	2 691	1 898	11 811	15 043	9 279	3 275
Raw materials and consumables used	-1 595	-1 305	-6 645	-11 854	-9 357	-2 909
Other external costs	-5 077	-23 295	-6 188	-9 910	-8 431	-7 203
Personnel costs	-5 147	-5 588	-4 692	-6 514	-6 984	-7 022
Depreciation of intangible assets and tangible assets	-481	-456	-570	-779	-710	-866
Other operating expenses	-165	-55	-65	-717	-587	-70
Total operating expenses	-12 465	-30 699	-18 160	-29 774	-26 069	-18 071
Operating income	-9 774	-28 801	-6 349	-14 731	-16 790	-14 795
Interest income	33	33	23	12	5	24
Interest expenses	-950	-1 023	-925	-1 081	-812	-805
Total result of financial items	-917	-990	-902	-1 069	-807	-781
Operating income after financial items	-10 691	-29 791	-7 251	-15 800	-17 597	-15 576
Tax	0	0	0	0	0	3
Net income	-10 691	-29 791	-7 251	-15 800	-17 597	-15 573
Average number of shares before dilution	7 073 342	7 073 342	7 073 342	7 073 342	17 037 595	17 037 595
Average number of shares after dilution ¹⁾	13 439 349	13 439 349	12 055 469	12 055 469	26 110 541	26 152 090
Outstanding shares at the end of the reporting period before dilution ^{1, 2)}	16 976 019	16 976 019	17 037 595	17 037 595	35 183 487	35 266 585
Outstanding shares at the end of the reporting period after dilution at full utilization. ²⁾	19 850 218	19 850 218	19 850 218	19 850 218	39 719 960	39 823 058
Outstanding warrants at the end of the reporting period ³⁾	2 874 199	2 874 199	2 812 623	2 812 623	4 536 473	4 556 473
Earnings per share before dilution, SEK ^{4, 5)}	-1,51	-4,21	-1,03	-2,23	-1,03	-0,91

¹⁾ In September 2021, 61,576 warrants were exercised to subscribe for the same number of shares, which added 61,576 new shares to the company. The number of shares increased to 17,037,595.

²⁾ In March 2022 a share issue was conducted which added the company 18,145,892 new shares which increased the number shares to 35,183,487 shares.

In May 2022, a warrant holder, TO3, redeemed; in their options for shares, which added 3,098 shares to the company, moreover chose one guarantor to receive shares instead of liquid compensation, which added an additional 80,000 shares to the company, which has increased the number of shares to 35,266,585 shares


³⁾ The rights issue was carried out in the form of units and the result of the rights issue resulted in 4,536,473 pending warrants.

⁴⁾ The subscription price of the warrants was within the interval for the current share price SEK 1,20 as of June 30, 2022.

⁵⁾ Earnings per share after dilution are reported only in the event that a conversion of potential ordinary shares in a lower profit or higher loss per share

Statement of Cash Flows isolated quarters

KSEK	2021 Iso. Q1	2021 Iso. Q2	2021 Iso. Q3	2021 Iso. Q4	2022 Iso. Q1	2022 Iso. Kv.2
OPERATING ACTIVITIES						
Profit/loss before tax	-9 774	-28 801	-6 349	-14 731	-16 790	-14 795
Financial income and expenses	-917	-990	-902	-1 071	-807	-781
<i>Adjustments for non-cash items:</i>						
Contribution from EU	369	48	-417	0	0	-
Depreciation/amortization and impairment	481	456	570	779	710	866
Cash flow from operating activities before changes in working capital	-9 841	-29 287	-7 098	-15 023	-16 887	-14 710
<i>Cash flow from changes in working capital</i>						
Increase(-)/decrease(+) inventories	1 191	-563	-5 705	2 311	-2 820	-3 567
Increase(-)/decrease(+) trade receivables	-8 179	468	-2 822	3 901	-1 036	3 002
Increase(-)/decrease(+) current receivables	-3 299	47	947	5 172	-487	1 451
Increase(+)/decrease(-) trade payables	-786	-635	4 417	-3 373	5 260	-5 509
Increase(+)/decrease(-) current liabilities	1 264	13 850	-4 841	-868	2 794	-3 638
Cash flow from changes in working capital	-9 809	13 167	-8 004	7 143	3 711	-8 261
Cash flow from operating activities	-19 650	-16 120	-15 102	-7 880	-13 176	-22 971
INVESTING ACTIVITIES						
Acquisition of intangible assets	-1 717	-1 414	-1 153	-701	-814	-2 256
Acquisition of tangible assets	-2 689	-3 149	-4 498	-670	-298	-798
Cash flow from investing activities	-4 406	-4 563	-5 651	-1 371	-1 112	-3 055
FINANCING ACTIVITIES						
New share issue	-152	-4	472	-10	44 874	-390
Repayment of leasing debt	0	0	0	-102	-44	-83
Cash flow from financing activities	-152	-4	472	-112	44 830	-472
CASH FLOW FOR THE PERIOD	-24 208	-20 687	-20 281	-9 363	30 542	-26 498
CASH AND CASH EQUIVALENTS AT START OF THE PERIC	93 390	69 182	48 495	28 214	18 851	49 393
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	69 182	48 495	28 214	18 851	49 393	22 895



ChromoGenics

We make properties more attractive

ChromoGenics AB

Ullforsgatan 15, 752 28 Uppsala, Sweden, Tel: +46 (18) 430 04 30

Email: info@chromogenics.com, www.chromogenics.com